The COSMYC Trial (COmbined Suppression of MYC) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

The COSMYC Trial (COmbined Suppression of MYC) — Stella

Home/Metastatic Castration-resistant Prostate Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Metastatic Castration-resistant Prostate Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Key details

Phase

Safety & dosing

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

Zenith Epigenetics, National Cancer Institute (NCI)

Enrollment target

~50 participants

Started

August 2025

Primary completion

August 2031

Age range

18 Years and older

Sex

Male only

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.